Product manufactured by Apotex Corp.

Application Nr Approved Date Route Status External Links
ANDA075191 1999-06-09 Oral RX Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Pentoxifylline Extended-Release Tablets Are Indicated For The Treatment Of Patients With Intermittent Claudication On The Basis Of Chronic Occlusive Arterial Disease Of The Limbs. Pentoxifylline Can Improve Function And Symptoms But Is Not Intended To Replace More Definitive Therapy, Such As Surgical Bypass, Or Removal Of Arterial Obstructions When Treating Peripheral Vascular Disease.

All Formulated Excipients (4 Total)

Name Structure Kind Function Status
1. Silicon Dioxide SILICON DIOXIDE Unresolved AC-Anticaking agent , MISC-Miscellaneous , STAB-Stabilizer GRAS-Generally recognized as safe.
2. Hypromelloses HYPROMELLOSES Unresolved
3. Magnesium Stearate MAGNESIUM STEARATE Molecular AF-Antifoaming (or defoaming) agent , MISC-Miscellaneous REG-Food additives for which a petition has been filed and a regulation issued.
4. Polyethylene Glycols POLYETHYLENE GLYCOLS Unresolved

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Pentoxifylline PENTOXIFYLLINE ZINC1530776